Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A11 | P48066 | 6/20 | 0.50 |
| ▸ | SLC6A1 | P30531 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.45 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.45 |
| ▸ | KIF11 | P52732 | 5/20 | 0.44 |
| ▸ | DUT | P33316 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6838771 | 0.93 | SLC6A11 (0.45) | SLC6A11SLC6A1MEN1TP53CYP1A2 | |
| SCHEMBL7926252 | 0.88 | KIF11 (0.52) | SLC6A11SLC6A1KIF11DUT | |
| SCHEMBL6707492 | 0.87 | SLC6A1 (0.49) | SLC6A11SLC6A1MEN1TP53CYP1A2 | |
| SCHEMBL26626984 | 0.87 | SLC6A1 (0.49) | SLC6A11SLC6A1MEN1TP53CYP1A2 | |
| SCHEMBL1594763 | 0.87 | KIF11 (0.50) | SLC6A11SLC6A1KMT2AKIF11DUT | |
| SCHEMBL26305210 | 0.87 | KIF11 (0.50) | SLC6A11SLC6A1KMT2AKIF11DUT | |
| SCHEMBL30861823 | 0.84 | SLC6A11 (0.53) | SLC6A11SLC6A1MEN1TP53CYP1A2 | |
| SCHEMBL2400336 | 0.83 | SLC6A11 (0.46) | SLC6A11SLC6A1MEN1TP53CYP1A2 | |
| SCHEMBL2385290 | 0.83 | SLC6A11 (0.46) | SLC6A11SLC6A1MEN1TP53CYP1A2 | |
| SCHEMBL6040158 | 0.83 | SLC6A11 (0.46) | SLC6A11SLC6A1MEN1TP53CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6762281-B2 | GENERATING PREFERENTIAL OLIGOMERS; GENERATE OLIGOMER, DEPROTECT, EXPOSE TO PHOSPHOROUS, OXIDIZE, EXPOSE TO SULFUR, CLEAVE, RECOVER PRODUCT | ISIS PHARMACEUTICALS, INC. | 2004-07-13 | — | — | US | disclosed |
| US-20040019000-A1 | Polyalkyleneamine-containing oligomers | ISIS PHARMACEUTICALS, INC. | 2004-01-29 | — | — | US | disclosed |
| US-20020156235-A1 | Process for preparing peptide derivatized oligomeric compounds | IONIS PHARMACEUTICALS, INC. | 2002-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156235-A1 | Process for preparing peptide derivatized oligomeric compounds | IAPP, PTMS, NGLY1 | SLC6A11 4309/4885SLC6A1 4635/4885MEN1 398/4885 |
| US-20040019000-A1 | Polyalkyleneamine-containing oligomers | FUS, NSF, PICALM | SLC6A11 383/4885SLC6A1 277/4885MEN1 1650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.